Bruker Corporation Acquires Prolab Instruments GmbH

Bruker Corporation Acquires biocrates life sciences ag

June 3, 2025

Biotechnology

Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.

Bruker Corporation Acquires PepSep (nanoLC columns maker)

February 4, 2022

Medical Devices

Bruker Corporation acquired PepSep, a Danish maker of nanoflow liquid chromatography (nanoLC) columns, emitters and components to expand its timsTOF 4D‑Proteomics consumables portfolio. Financial terms were not disclosed; Bruker also announced an OEM agreement with IonOpticks to produce Bruker-branded high-performance pulled-tip columns.

Bruker Acquires Dynamic Biosensors GmbH

October 2, 2024

Biotechnology

Bruker Corporation has acquired Dynamic Biosensors GmbH, a Munich-based developer of single-cell interaction cytometry and biosensor instruments, to strengthen Bruker’s biosensors portfolio. The deal combines Dynamic Biosensors’ heliXcyto and heliX+ technologies with Bruker’s high-throughput SPR systems to expand capabilities and product offerings for drug discovery and biopharma research; financial terms were not disclosed.

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.

Bruker Corporation Acquires PhenomeX Inc.

August 17, 2023

Biotechnology

Bruker Corporation agreed to acquire PhenomeX Inc. in an all-cash transaction valued at roughly $108 million (purchase price $1.00 per share). PhenomeX — formed from the combination of Berkeley Lights and IsoPlexis and provider of single-cell biology instruments, software and reagents — will be folded into a Bruker subsidiary, marking Bruker’s entry into single-cell biology research tools and complementing its spatial biology offerings.

Bruker Corporation Acquires NanoString Technologies Business

May 6, 2024

Medical Devices

Bruker Corporation has acquired substantially all assets of NanoString Technologies, Inc. through a court-supervised Chapter 11 asset sale for approximately $392.6 million in cash plus assumption of certain liabilities. The deal, announced April 2024 and closed in late April/early May 2024, brings NanoString's spatial biology and gene-expression product lines into Bruker to preserve customer access, product development, and jobs while expanding Bruker's life‑science instrumentation capabilities.